Seres Therapeutics Inc (NAS:MCRB)
$ 0.7589 -0.017 (-2.19%) Market Cap: 114.94 Mil Enterprise Value: 221.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Seres Therapeutics Inc SER-287 Clinical Data Update Call Transcript

Jun 21, 2021 / 12:30PM GMT
Release Date Price: $22.46 (+2.89%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Ulcerative Colitis Webcast. (Operator Instructions) I would now like to introduce your host for this conference call, Mr. Eric Shaff, CEO. You may begin.

Eric D. Shaff
Seres Therapeutics, Inc. - President, CEO & Director

Good morning, and welcome to Seres Therapeutics Ulcerative Colitis Investor Webcast. Thank you for spending time with us this morning. We will be reviewing slides alongside our remarks, and we have posted the presentation under the Investors and News section of the Seres website.

Our primary goal for today is to provide a better understanding and appreciation of our work to develop novel microbiome therapeutics for ulcerative colitis. We will be discussing our ongoing SER-287 ulcerative colitis Phase IIb study, with top line clinical results expected midyear, followed by additional data later this year. We will also be highlighting SER-301, our next-generation product candidate. We are excited about the prospects for both programs as potentially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot